188 related articles for article (PubMed ID: 17061398)
1. Off-label uses of bevacizumab: breast and lung cancer indications.
Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(8):1-4. PubMed ID: 17061398
[No Abstract] [Full Text] [Related]
2. Off-label uses of bevacizumab: renal cell carcinoma and other miscellaneous non-colorectal cancer indications.
Technol Eval Cent Assess Program Exec Summ; 2006 Oct; 21(9):1-4. PubMed ID: 17061399
[No Abstract] [Full Text] [Related]
3. Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.
Prescrire Int; 2009 Feb; 18(99):11. PubMed ID: 19385126
[TBL] [Abstract][Full Text] [Related]
4. Exploring the future of non-small cell lung cancer treatment.
Ramalingam S
Manag Care; 2005 Feb; 14(2 Suppl):9-13; discussion 13-4. PubMed ID: 15776956
[No Abstract] [Full Text] [Related]
5. Off-label uses of sorafenib and sunitinib.
Technol Eval Cent Assess Program Exec Summ; 2008 Feb; 22(11):1-4. PubMed ID: 18411502
[No Abstract] [Full Text] [Related]
6. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
7. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?
Eskens FA; Sleijfer S
Eur J Cancer; 2008 Nov; 44(16):2350-6. PubMed ID: 18789679
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
9. Multitargeted inhibitors in lung cancer: new clinical data.
Bar J; Herbst RS; Onn A
Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
[TBL] [Abstract][Full Text] [Related]
10. FDA and Avastin: crossroads in an era of targeted therapies.
Tripathy D
Oncology (Williston Park); 2010 Oct; 24(11):989-90. PubMed ID: 21155445
[No Abstract] [Full Text] [Related]
11. [Targeted therapies for lung cancer].
Tamura K
Rinsho Ketsueki; 2008 Aug; 49(8):616-21. PubMed ID: 18800610
[No Abstract] [Full Text] [Related]
12. [Bevacizumab in the treatment of non-small cell lung cancer].
Knuuttila A; Rouhos A; Karjalainen EM; Riska H; Pietiläinen M; Paunu N; Salomaa ER
Duodecim; 2009; 125(4):361-8. PubMed ID: 19358416
[TBL] [Abstract][Full Text] [Related]
13. The FDA approves drugs for colorectal cancer, lung cancer.
FDA Consum; 2007; 41(1):5. PubMed ID: 17354284
[No Abstract] [Full Text] [Related]
14. Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
Expert Rev Anticancer Ther; 2003 Jun; 3(3):257. PubMed ID: 12820770
[No Abstract] [Full Text] [Related]
15. Developing targeted therapies for lung cancer.
Gandara DR
Clin Adv Hematol Oncol; 2003 Nov; 1(11):648-9, 690. PubMed ID: 16258461
[No Abstract] [Full Text] [Related]
16. [The actual place of anti-angiogenesis in non-small cell lung cancer].
Mennecier B
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S198-205. PubMed ID: 18235414
[TBL] [Abstract][Full Text] [Related]
17. [Angiogenesis and lung cancer].
Pérol M; Arpin D
Bull Cancer; 2007 Jul; 94 Spec No():S220-31. PubMed ID: 17846008
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibitors in the treatment of lung cancer.
Sun S; Schiller JH
Crit Rev Oncol Hematol; 2007 May; 62(2):93-104. PubMed ID: 17306557
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
Lorusso PM; Boerner SA; Hunsberger S
J Clin Oncol; 2011 Aug; 29(22):2952-5. PubMed ID: 21709201
[No Abstract] [Full Text] [Related]
20. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
Blackhall FH; Shepherd FA
Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
